Oral pemphigoid. Subset of cicatricial pemphigoid?
OBJECTIVE
Cicatricial pemphigoid (CP) is an autoimmune blistering disease characterized by anti-basement membrane zone (BMZ) antibodies with a varied heterogeneous clinical spectrum. We sought to characterize a subset of patients with disease limited to the oral cavity.


METHODS
Twenty-nine random patients with vesiculobullous disease limited to the oral cavity were studied. We identified patients by clinical criteria, the presence of subepidermal/subepithelial bullae on routine histopathologic study, and deposition of IgG, complement, or both on the BMZ of perilesional tissue by immunopathological studies. Treatment included local and systemic therapies. Patients were monitored for a mean period of 6.7 years (range, 3.5 to 11 years).


RESULTS
The female/male ratio was 4.8:1. Patients with limited or minimal disease received local therapy only. In patients with extensive or severe disease, the use of dapsone yielded significant clinical improvement. Long-term follow-up showed that patients with severe disease treated with dapsone followed a clinical course similar to that in patients with minimal disease.


CONCLUSIONS
Oral pemphigoid is a distinct clinical subset of CP. Overall it has a relatively benign course compared with that in patients with CP involving the oral cavity and other mucosae and the skin. Patients with minimal disease respond satisfactorily to topical therapy. Patients with severe and extensive disease benefit from dapsone therapy. In most patients the clinical course is prolonged and treatment is required for several months; in our study the mean treatment period was 42 months (range, 24 to 78 months). All the patients in this study went into clinical remission and remained in remission on cessation of therapy. No other mucosae or the skin were involved during the follow-up period.
Mobini
N
N
Center for Blood Research, Harvard Medical School, Harvard School of Dental Medicine, Boston, Mass., USA.
Nagarwalla
N
N
Ahmed
A R
AR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies; D001485:Basement Membrane / Q000276:immunology; D003622:Dapsone / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000209:etiology; D005891:Gingivitis / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009061:Mouth Mucosa / Q000473:pathology; D009067:Mouthwashes / Q000627:therapeutic use; D010391:Pemphigoid, Bullous / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
D000906:Antibodies; D009067:Mouthwashes; D003622:Dapsone